1. Metabolic Enzyme/Protease
  2. Pyruvate Dehydrogenase

Pyruvate Dehydrogenase

Pyruvate dehydrogenase is the first component enzyme of pyruvate dehydrogenase complex (PDC). The pyruvate dehydrogenase complex contributes to transforming pyruvate into acetyl-CoA by a process called pyruvate decarboxylation. Acetyl-CoA may then be used in the citric acid cycle to carry out cellular respiration, so pyruvate dehydrogenase contributes to linking theglycolysis metabolic pathway to the citric acid cycle and releasing energy via NADH.

Pyruvate dehydrogenase performs the first two reactions within the pyruvate dehydrogenase complex (PDC): a decarboxylation of substrate 1 (pyruvate) and a reductive acetylation of substrate 2 (lipoic acid). Lipoic acid is covalently bound to dihydrolipoamide acetyltransferase, which is the second catalytic component enzyme of PDC. The reaction catalyzed by pyruvate dehydrogenase is considered to be the rate-limiting step for the pyruvate dehydrogenase complex (PDHc).

Pyruvate Dehydrogenase Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-18657
    TEPP-46 Activator 99.35%
    TEPP-46 is a potent and selective activator of recombinant pyruvate kinase M2 (PKM2) with half-maximum activating concentration (AC50 value) of 92 nM, and has little or no effect on PKM1, PKL and PKR.
  • HY-N0822
    Shikonin Inhibitor 99.64%
    Shikonin is an inhibitor of TMEM16A chloride channel with an IC50 of 6.5 μM. Shikonin is also a specific inhibitor of PKM2 and can also inhibit tumor necrosis factor-α (TNF-α) and prevent activation of nuclear factor-κB (NF-κB) pathway.
  • HY-15453
    CPI-613 Inhibitor 99.59%
    CPI-613 is an E1(alpha) pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.
  • HY-103617
    PKM2-IN-1 Inhibitor 98.35%
    PKM2-IN-1 is a pyruvate kinase M2 (PKM2) inhibitor with an IC50 of 2.95 μM.